AIM ImmunoTech enters its May 18 earnings release having shed more than half its value in a single month — and with every major short-side signal moving in the same direction at once: covering, cheaper borrows, and a lending pool that just reopened.
The price collapse is the headline. Shares closed at $0.253 on Friday, a 56% fall over the past month and 25% down on the week alone. Against that backdrop, the stock's short positioning is doing something counterintuitive: it is retreating. Short interest as a percentage of the free float fell from roughly 9% at the start of this week to 7.1% by May 14, a 22% week-on-week decline in shares held short. Over the last month, however, SI % FF has risen 56% — so the net picture is that shorts who piled in during April are now covering into the weakness. The ORTEX short score dropped to 47 by May 14, down from 67 just four days earlier on May 11, confirming the rapid de-escalation of bearish conviction in the lending market.
The borrow story is equally striking. Cost to borrow peaked above 340% APR in early April and has been grinding lower ever since, reaching 191% by May 14 — still extraordinarily expensive by any conventional measure, but a near-halving from those April extremes. More telling is what happened to availability this week: utilization collapsed from 75%–81% through the first week of May to just 9.9% by May 14. That means the lending pool went from tightly constrained — fewer than one share available per four already borrowed — to comfortably open almost overnight. When borrow availability loosens this abruptly into a falling price, it typically reflects short sellers returning shares en masse rather than new supply entering the market.
The Street offers little additional signal. A single analyst, Ascendiant Capital, covers the stock — and cut its target to $10 in early April from $22, continuing a long series of reductions (the prior target was $24, before that $150). The current $10 target sits roughly 40 times above the current share price of $0.253, a gap that almost certainly reflects share structure changes and should not be read as conventional upside. The bull case rests on Ampligen's clinical pipeline — colorectal cancer, post-COVID, pancreatic cancer — while the bear case is grounded in ongoing net losses, liquidity constraints, and the structural risks of late-stage biotech. The EPS surprise factor score ranks in the 87th percentile, and the days-to-cover rank is in the 84th percentile, but with a float this small and institutional ownership this thin, those scores carry limited weight in the conventional sense.
Insider activity adds a modest layer of context. CEO Thomas Equels and director David Chemerow each bought $25,000 of stock in early March at around $1,000 per share — consistent with a post-reverse-split price structure — and Chemerow had acquired shares at market in February as well. The net insider position over 90 days is a buy of roughly $53,000 in value. Against a stock that has since fallen more than 75% from those March levels, the conviction behind those purchases has been tested severely.
The earnings print on May 18 is the next hard marker. The past three confirmed releases have all produced sharp moves: a 20% single-day drop in March 2026, a 5.7% fall in November 2025, and a 3.8% gain with a 17% five-day follow-through on the prior November 2025 event. Peers VCEL and ONCY both closed the week modestly lower, down 1.3% and 4.5% respectively, offering no particular sector read for AIM's trajectory. With shorts covering, borrow loosening, and a near-term catalyst on the calendar, the question for Monday's release is less about positioning pressure and more about whether the clinical narrative gives investors any reason to arrest a month-long decline.
See the live data behind this article on ORTEX.
Open AIM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
